This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

Artrite Reumatóide

Home/Publicações/Artrite Reumatóide

Effect of Prednisone on Type I Interferon Signature in Rheumatoid Arthritis

2016-07-13T08:30:10+00:00 2015-7-15|Categories: Artrite Reumatóide|

Consequences for Response Prediction to Rituximab Tamarah D de Jong; Saskia Vosslamber; Marjolein Blits; Gertjan Wolbink; Mike T Nurmohamed; Conny J van der Laken; Gerrit Jansen; Alexandre E Voskuyl; Cornelis L Verweij Abstract Introduction Elevated type I interferon (IFN) response gene (IRG) expression has proven clinical relevance in predicting rituximab non-response in rheumatoid arthritis (RA). Interference between [...]

Etanercept for patients with RA: more is not always better

2016-07-13T08:32:45+00:00 2014-12-1|Categories: Artrite Reumatóide, Uncategorized|

Joel M Kremer Abstract Weinblatt and colleagues have studied the efficacy and safety of etanercept 50 mg twice weekly in comparison with etanercept 50 mg once weekly in patients with longstanding rheumatoid arthritis. The study failed to demonstrate any clinically meaningful or statistically significant benefit of the use of the twice weekly dosage. There was also [...]

Deficient spontaneous in vitro apoptosis and increased tmTNF reverse signaling-induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition

2016-07-13T08:34:25+00:00 2014-1-20|Categories: Artrite Reumatóide|

Abstract Introduction: In vitro apoptosis of peripheral monocytes in rheumatoid arthritis (RA) is disturbed and influenced by cytokine production and transmembrane TNF (tmTNF) reverse signaling. The goal of the study was the analysis of the predictive value of the rate of in vitro apoptosis for the therapeutic response to anti-TNF treatment. Methods: Spontaneous and tmTNF reverse signaling-induced apoptosis [...]

Towards the elucidation of the true impact of adipocytokines on cardiovascular risk in rheumatoid arthritis

2016-10-16T12:02:12+00:00 2014-1-20|Categories: Artrite Reumatóide|

Abstract Adipo(cyto)kines are mostly produced by adipose tissue and orchestrate the adverse impact of excess adiposity on cardiovascular risk. Adipokines also contribute importantly to the pathophysiology of rheumatoid arthritis. Congruent with data reported in previous investigations, Kang and colleagues report in this issue of Arthritis Research & Therapy that adipokine concentrations are further associated with metabolic risk and [...]

What autoantibody tests should become widely available to help scleroderma diagnosis and management?

2016-07-13T08:37:33+00:00 2013-7-19|Categories: Artrite Reumatóide|

Abstract Anti-Th/To autoantibodies have been recognized as serological markers of systemic sclerosis (SSc) for more than 20 years. However, validated immunoassay kits to test this specifi city have not been commercially available. SSc autoantibodies are basically mutually exclusive and are associated with a certain subset of the disease and/or with organ involvement. Anti-Th/ To are generally considered to be markers of the limited cutaneous [...]

Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis

2016-10-16T12:02:12+00:00 2013-7-19|Categories: Artrite Reumatóide|Tags: , , , , |

Arthritis Research & Therapy 2013, 15:R72 doi:10.1186/ar4249 Federico Perosa (federico.perosa@uniba.it) Elvira Favoino (elvira.favoino@uniba.it) Giovanna Cuomo (Giovanna.CUOMO@unina2.it) Liboria Digiglio (l.digiglio@alice.it) Franco Dammacco (francodam@dimo.uniba.it) Marcella Prete (marcella.prete@uniba.it) Gabriele Valentini (gabriele.valentini@unina2.it) Vito Racanelli (vito.racanelli1@uniba.it) Abstract Introduction: In a subset of patients with limited cutaneous (lc) systemic sclerosis (SSc), antiCENP-A antibodies (Ab) cross-react with a peptide (FOXE3p53-62) that presents striking homology with one of the 2  immunodominant epitopes of [...]

New Rheumatoid Arthritis Guidelines Released

2016-10-16T12:02:12+00:00 2013-7-16|Categories: Artrite Reumatóide|

Medscape Medical News, 2013-06-24 MADRID, Spain — The European League Against Rheumatism (EULAR) guidelines, unveiled here at the 2013 congress, are being updated from 2010 and contain notable differences from the new American College of Rheumatology recommendations. The guidelines, which are not yet published, focus on the efficacy of conventional disease-modifying antirheumatic drugs (DMARDs) as first-line therapy, [...]

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

2016-10-16T12:02:13+00:00 2013-7-12|Categories: Artrite Reumatóide|

James R. O’Dell, M.D., Ted R. Mikuls, M.D., M.S.P.H., Thomas H. Taylor, M.D., Vandana Ahluwalia, M.D., Mary Brophy, M.D., M.P.H., Stuart R. Warren, J.D., Pharm.D., Robert A. Lew, Ph.D., Amy C. Cannella, M.D., Gary Kunkel, M.D., Ciaran S. Phibbs, Ph.D., Aslam H. Anis, Ph.D., Sarah Leatherman, M.A., and Edward Keystone, M.D., for the CSP 551 RACAT Investigators Background Few [...]

A New Chapter in Rheumatoid Arthritis Therapeutics

2016-07-13T08:41:42+00:00 2013-2-13|Categories: Artrite Reumatóide|

Introduction Without much doubt, the most significant development in rheumatoid arthritis (RA) therapeutics during the past year has been the advancement of the first small-molecular agent in many years, the Janus kinase (JAK) inhibitor tofacitinib (Xeljanz™), to clinical use in the United States. Use in Europe is probably around the corner. The identification and detailed description [...]

Head-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab for Rheumatoid Arthritis

2016-10-16T12:02:13+00:00 2013-1-18|Categories: Artrite Reumatóide|

Findings of a Phase IIIb, Multinational, Prospective, Randomized Study Michael E. Weinblatt, Michael Schiff, Robert Valente, Désireé van der Heijde, Gustavo Citera, Cathy Zhao, Michael Maldonado, and Roy Fleischmann Objective. There is a need for comparative studies to provide evidence-based treatment guidance for biologic agents in rheumatoid arthritis (RA). Therefore, this study was undertaken as the first head-to-head comparison of subcutaneous (SC) abatacept and SC adalimumab, both [...]